Unlike orthosteric IR activators, ligands that bind allosterically to IR and sensitize insulin action would represent a significant therapeutic advancement with the potential of alleviating insulin resistance and minimizing hypoglycemia risk. The gene discussed is INS; the disease is Hypoglycemia.